SBIR/STTR Research Award
Ordered Arrays for Advanced Sequencing Systems
Award amount
$2,645,800Program and phase
SBIR · Phase IIAward year
2010Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- INTELLIGENT BIO-SYSTEMS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PHS2010-2
- Topic code
- NHGRI
Research abstract
DESCRIPTION (provided by applicant): The advent of next-generation sequencing technologies is allowing researchers to perform studies and make discoveries which previously were not economically or technically feasible. Thus far, however, higher-throughput next-generation sequencing systems are relatively expensive, have relatively long run times and produce relatively short reads thereby limiting their use for diagnostic applications. In this Phase II application, we propose to combine the novel chip fabrication techniques developed in Phase I, the innovative sequencing by synthesis chemistry exclusively licensed from Columbia University, and an automated prototype sequencing instrument to produce an advanced sequencing by synthesis system. This system will be higher throughput and significantly more cost effective than other competing next-generation technologies. During the project, high density chips will be fabricated, the sequencing instrument and chemistry will be optimized and an E. coli genome will be re-sequenced. This system will be capable of producing large amounts of quality sequence data faster and at a lower cost than any other near-term next generation sequencing system. This will make next-generation DNA sequencing technology more accessible to the broad research community. PUBLIC HEALTH RELEVANCE: Ultimately, the ability to produce very inexpensive detailed DNA sequence information for complex organisms' genomes will both lead to accelerated discoveries throughout biology and provide the basis for Pharmacogenomics, a new paradigm in therapeutics wherein medicines are prescribed based on individual genotypes rather than just observed symptoms.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Platform to support clinical variant interpretation through probabilistic assessment of functional evidence
- Innovations to expand and accelerate the commercial impact of DNA modifications
- High-throughput Direct Sequencing and Quantitative Mapping of RNA Modifications using Mass Spectrometry.
- Super-resolution single-molecule sequencing by observing the dynamic hybridization of a repertoire of oligonucleotides to DNA targets
- Exhaustive de novo sequencing of every RNA in a sample by a layer-by-layer mass spectrometry ladder intensity approach.